Strata Critical Medical, Inc. (SRTA) - 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Strata Critical Medical, Inc. (formerly Blade Air Mobility, Inc.) operates as a time-critical logistics and medical services provider for the U.S. healthcare industry, focusing on organ transplant logistics and clinical services. The company operates two segments: Logistics (Trinity brand) and Clinical (Keystone brand).
During 2025, the company underwent a strategic transformation:
- Divestiture: Sold its Passenger business to Joby Aero, Inc. on August 29, 2025, for approximately $76.0 million in Joby stock (net proceeds of $70.2 million). This business is reported as discontinued operations.
- Acquisition: Acquired Keystone Perfusion Services, LLC on September 16, 2025, for approximately $111.3 million in cash and stock, establishing its Clinical segment.
- Rebranding: Rebranded from Blade Air Mobility to Strata Critical Medical to reflect its focused medical services strategy.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue (Continuing Ops) | $197,141 | $146,817 | +34.3% |
| Gross Profit | $41,126 | $29,589 | +39.0% |
| Gross Margin | 21% | 20% | +100 bps |
| Operating Loss (Continuing Ops) | $(22,353) | $(22,525) | -0.8% |
| Net Loss (Continuing Ops) | $(20,066) | $(16,161) | -24.2% |
| Net Income (Total, incl. Discontinued) | $41,347 | $(27,307) | NM |
| Adjusted EBITDA | $14,051 | $3,752 | +274% |
| Cash & Equivalents | $31,000 | $16,100 | N/A |
| Total Liquidity | $61,200 | $124,800 | -50.9% |
Note: Total liquidity includes cash, cash equivalents, and short-term investments. The decrease in liquidity is primarily due to the acquisition of Keystone and the sale of short-term investments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $50.3 million (34.3%). Logistics revenue grew 20.4% to $176.8 million. Clinical revenue was $20.3 million, entirely from the Keystone acquisition (no clinical revenue in 2024).
- Profitability: While the company reported a net loss from continuing operations of $20.1 million, Adjusted EBITDA improved significantly to $14.1 million, driven by gross profit expansion and operational leverage.
- Discontinued Operations: The sale of the Passenger business resulted in a $61.4 million net income from discontinued operations in 2025, compared to an $11.1 million loss in 2024. This includes a $57.0 million gain on disposal.
- Expenses: SG&A expenses increased 19.7% to $60.9 million, driven by professional fees (including $4.7 million for the settlement of the Drulias class action lawsuit) and M&A transaction costs. Stock-based compensation decreased 8.2% due to forfeitures related to the former CEO's transfer to Joby.
- Asset Base: The company owns 10 fixed-wing aircraft (9 fully owned, 1 in escrow) as of year-end, continuing its shift from a purely asset-light model to a hybrid model.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management anticipates sufficient funds to meet operational needs for the next 12 months based on current liquidity of $61.2 million. In January 2026, the company entered into a $30.0 million asset-based revolving credit facility (with a $20.0 million accordion feature) to provide additional financial flexibility.
Key Risks and Contingencies:
- Profitability: The company continues to incur net losses from continuing operations and may not achieve profitability in the near term.
- Integration: Risks associated with integrating Keystone and realizing anticipated synergies from the divestiture of the Passenger business.
- Regulatory & Legal: The company operates in highly regulated healthcare and aviation environments. A class action lawsuit regarding the prior acquisition of Blade Urban Air Mobility was settled in December 2025.
- Operational: Dependence on third-party aircraft operators, availability of donor organs, and potential for delivery failures impacting organ viability.
- Warrant Liability: Public and Private Placement Warrants are classified as liabilities and remeasured at fair value, causing volatility in earnings based on stock price fluctuations.
Investor Verification Checklist
- Continuing Operations Viability: Verify the path to profitability for continuing operations, given the $20.1 million net loss excluding the one-time gain from the Passenger business sale.
- Keystone Integration: Assess the performance of the newly acquired Clinical segment (Keystone) and the realization of projected synergies.
- Liquidity Position: Monitor the utilization of the new $30 million credit facility and the company's ability to fund operations without further equity dilution.
- Warrant Liability Impact: Review the fair value adjustments of warrant liabilities, which contributed $4.3 million to non-operating income in 2025 but can create significant earnings volatility.
- Customer Concentration: Note that three customers affiliated with the same national hospital group represented 11% of 2025 revenue.
- Asset Ownership Risks: Evaluate the financial impact of owning aircraft (maintenance, depreciation, impairment) versus the asset-light model, including the $1.7 million impairment charge recorded in 2025.